Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension.

OBJECTIVE Lung transplantation is a viable, life-saving intervention for several primary pulmonary disorders complicated by severe lung dysfunction. This study was undertaken to evaluate whether patients with systemic sclerosis (scleroderma), a systemic autoimmune rheumatic disorder, would receive similar benefit from this intervention. METHODS Survival following lung transplantation was examined at 2 university medical centers among 29 patients with scleroderma as compared with 70 patients with idiopathic pulmonary fibrosis (IPF) and 38 with idiopathic pulmonary arterial hypertension (IPAH), the latter groups representing pathologically related primary pulmonary disorders. The end point was death from any cause. Risk of mortality in patients with scleroderma was compared with that in patients with IPF or IPAH, with adjustment for demographic and clinical parameters. RESULTS During 2 years of followup, 11 patients with scleroderma (38%), 23 with IPF (33%), and 14 with IPAH (37%) died. Cumulative survival at 6 months posttransplantation was 69% in the scleroderma group compared with 80% in the IPF group (log-rank P = 0.21) and 79% in the IPAH group (P = 0.38). The estimated risk of mortality at 6 months was increased in patients with scleroderma compared with those with IPF (relative risk [RR] 1.70, 95% confidence interval [95% CI] 0.74-3.93) and those with IPAH (RR 1.52, 95% CI 0.59-3.96), but the differences were not statistically significant. Over the following 18 months, there was convergence in the survival rates such that cumulative survival at 2 years was comparable, at approximately 64%, among all 3 groups. CONCLUSION Patients with scleroderma who are recipients of lung transplantation experience similar rates of survival 2 years after the procedure compared with those with IPF or IPAH. Lung transplantation may represent a viable therapeutic option to consider for patients with end-stage lung disease due to scleroderma.

[1]  E. Bleecker,et al.  Therapeutic responses in asthma and COPD. Corticosteroids. , 2004, Chest.

[2]  I. Rubinstein,et al.  Inflammation and obstructive sleep apnea syndrome: how many ways do I look at thee? , 2004, Chest.

[3]  Marshall I Hertz,et al.  The registry of the International Society for Heart and Lung Transplantation: twentieth official adult heart transplant report--2003. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  R. Barst,et al.  Bosentan therapy for pulmonary arterial hypertension. , 2002, The New England journal of medicine.

[5]  S. Anton,et al.  Impact of body weight on long-term survival after lung transplantation. , 2002, Chest.

[6]  D. Zander,et al.  Analysis of early deaths after isolated lung transplantation. , 2001, Chest.

[7]  T. Medsger,et al.  Criteria for the classification of early systemic sclerosis. , 2001, The Journal of rheumatology.

[8]  J. Dauber,et al.  Lung transplantation in patients with scleroderma. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[9]  R. Wise,et al.  Cyclophosphamide Is Associated with Pulmonary Function and Survival Benefit in Patients with Scleroderma and Alveolitis , 2000, Annals of Internal Medicine.

[10]  Stuart Rich,et al.  Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.

[11]  H. Spiera,et al.  Renal transplantation in scleroderma. , 1999, Medicine.

[12]  H. Spiera,et al.  Recurrence of scleroderma in a renal allograft from an identical twin sister. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  F. Martinez,et al.  International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[14]  M. Estenne,et al.  International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[15]  J. Bavaria,et al.  Primary graft failure following lung transplantation. , 1998, Chest.

[16]  B. Griffith,et al.  Lung transplantation for respiratory failure resulting from systemic disease. , 1997, The Annals of thoracic surgery.

[17]  J. Peters,et al.  Single lung transplantation in patients with systemic disease. , 1994, Chest.

[18]  M. H. Gault,et al.  Predicting glomerular function from adjusted serum creatinine. , 1992, Nephron.

[19]  D. Buskila,et al.  Mortality in systemic sclerosis (scleroderma). , 1992, The Quarterly journal of medicine.

[20]  M. Pasque,et al.  The Washington University-Barnes Hospital experience with lung transplantation. Washington University Lung Transplantation Group. , 1991, JAMA.

[21]  J. Costantino,et al.  Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. , 1990, Annals of internal medicine.

[22]  G. Patterson,et al.  Results of single-lung transplantation for bilateral pulmonary fibrosis. The Toronto Lung Transplant Group. , 1990, The New England journal of medicine.

[23]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[24]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[25]  C. J. Mcallister,et al.  Hemodialysis and renal transplantation in progressive systemic sclerosis: report of 2 cases. , 1979, Clinical nephrology.

[26]  R. Fleischmann,et al.  The management of renal scleroderma: experience with dialysis, nephrectomy and transplantation. , 1978, The American journal of medicine.

[27]  H. Seigler,et al.  Apparent recurrence of progressive systemic sclerosis in a renal allograft. , 1976, JAMA.

[28]  W. Keane,et al.  Successful renal transplantation in progressive systemic sclerosis. , 1976, Annals of internal medicine.

[29]  J. Richardson.  Hemodialysis and kidney transplantation for renal failure from scleroderma. , 1973, Arthritis and rheumatism.

[30]  J. Peto,et al.  Asymptotically Efficient Rank Invariant Test Procedures , 1972 .

[31]  A. Masi,et al.  Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. , 1971, Annals of internal medicine.

[32]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[33]  J. Orens,et al.  Lung transplantation and systemic sclerosis. , 2000, Annals of transplantation.

[34]  E. Spitznagel,et al.  Cytomegalovirus Infection and Pneumonitis: Impact after Isolated Lung Transplantation , 1993 .

[35]  D. Cox.  Regression Models and Life-Tables , 1972 .